These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23019714)

  • 41. Effectiveness and safety of laropiprant on niacin-induced flushing.
    Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
    Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.
    Ann Intern Med; 2005 Jan; 142(2):I46. PubMed ID: 15657152
    [No Abstract]   [Full Text] [Related]  

  • 43. High Niacin Levels May Raise Cardiovascular Disease Risk.
    Harris E
    JAMA; 2024 Mar; 331(12):1001. PubMed ID: 38446486
    [No Abstract]   [Full Text] [Related]  

  • 44. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol.
    Wright RS
    Curr Opin Cardiol; 2013 Jul; 28(4):389-98. PubMed ID: 23736814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The flavonoid luteolin inhibits niacin-induced flush.
    Papaliodis D; Boucher W; Kempuraj D; Theoharides TC
    Br J Pharmacol; 2008 Apr; 153(7):1382-7. PubMed ID: 18223672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of flushing due to niacin and abolition of these effects.
    Sood A; Arora R
    J Clin Hypertens (Greenwich); 2009 Nov; 11(11):685-9. PubMed ID: 19878384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HM74a agonists: will they be the new generation of nicotinic acid?
    Martres P
    Curr Top Med Chem; 2009; 9(5):428-35. PubMed ID: 19519459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nicotinic acid: an old drug with a promising future.
    Bodor ET; Offermanns S
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S68-75. PubMed ID: 18037924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.
    Dunbar RL; Goel H; Tuteja S; Song WL; Nathanson G; Babar Z; Lalic D; Gelfand JM; Rader DJ; Grove GL
    J Lipid Res; 2017 Apr; 58(4):783-797. PubMed ID: 28119443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Niacin--an additive therapeutic approach for optimizing lipid profile].
    Wieneke H; Schmermund A; Erbel R
    Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Important considerations for treatment with dietary supplement versus prescription niacin products.
    Backes JM; Padley RJ; Moriarty PM
    Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Niacin: chemical forms, bioavailability, and health effects.
    MacKay D; Hathcock J; Guarneri E
    Nutr Rev; 2012 Jun; 70(6):357-66. PubMed ID: 22646128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.
    Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ
    Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia].
    Kardiologiia; 1993; 33(11):67-80. PubMed ID: 8145429
    [No Abstract]   [Full Text] [Related]  

  • 55. Activation of HCAR2 by niacin: benefits beyond lipid lowering.
    Tuteja S
    Pharmacogenomics; 2019 Nov; 20(16):1143-1150. PubMed ID: 31617441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Secondary prevention of coronary disease with lipid-lowering drugs.
    Lancet; 1989 Mar; 1(8636):473-4. PubMed ID: 2563844
    [No Abstract]   [Full Text] [Related]  

  • 57. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease.
    Mason CM; Doneen AL
    J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
    Bays HE; Ballantyne C
    Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. When taking niacin to help lower my LDL and raise my HDL, I have experienced a hot and itchy "flushing" sensation, which I understand is very common. Are there any "no flush" niacin products on the market?
    Heart Advis; 2007 Nov; 10(11):8. PubMed ID: 18271102
    [No Abstract]   [Full Text] [Related]  

  • 60. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.